Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Dimed Distribuidora de Medicamentos

BOVESPA:PNVL3
Snowflake Description

Solid track record with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PNVL3
BOVESPA
R$3B
Market Cap
  1. Home
  2. BR
  3. Consumer Retailing
Company description

Dimed S.A. Distribuidora de Medicamentos engages in the commercialization of medication, perfumes, personal hygiene and beauty products, cosmetics, and dermocosmetics in Brazil. The last earnings update was 148 days ago. More info.


Add to Portfolio Compare Print
  • Dimed Distribuidora de Medicamentos has significant price volatility in the past 3 months.
PNVL3 Share Price and Events
7 Day Returns
14.8%
BOVESPA:PNVL3
-0.3%
BR Consumer Retailing
6.5%
BR Market
1 Year Returns
94.1%
BOVESPA:PNVL3
-3%
BR Consumer Retailing
-16.8%
BR Market
PNVL3 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Dimed Distribuidora de Medicamentos (PNVL3) 14.8% -5.4% 27.9% 94.1% 24% 262.4%
BR Consumer Retailing -0.3% -6.6% -13.2% -3% 6.5% 18.2%
BR Market 6.5% -11.6% -31.6% -16.8% 13.8% 22.6%
1 Year Return vs Industry and Market
  • PNVL3 outperformed the Consumer Retailing industry which returned -3% over the past year.
  • PNVL3 outperformed the Market in Brazil which returned -16.8% over the past year.
Price Volatility
PNVL3
Industry
5yr Volatility vs Market

PNVL3 Value

 Is Dimed Distribuidora de Medicamentos undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Dimed Distribuidora de Medicamentos to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Dimed Distribuidora de Medicamentos.

BOVESPA:PNVL3 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 14.4%
Perpetual Growth Rate 10-Year BR Government Bond Rate 7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BOVESPA:PNVL3
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year BR Govt Bond Rate 7%
Equity Risk Premium S&P Global 9.3%
Consumer Retailing Unlevered Beta Simply Wall St/ S&P Global 0.39
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.393 (1 + (1- 34%) (13.89%))
0.618
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 6.96% + (0.8 * 9.25%)
14.36%

Discounted Cash Flow Calculation for BOVESPA:PNVL3 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Dimed Distribuidora de Medicamentos is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BOVESPA:PNVL3 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (BRL, Millions) Source Present Value
Discounted (@ 14.36%)
2020 -14.20 Analyst x1 -12.42
2021 40.70 Analyst x1 31.12
2022 89.10 Analyst x2 59.57
2023 69.40 Analyst x1 40.58
2024 100.40 Analyst x1 51.33
2025 117.45 Est @ 16.98% 52.51
2026 133.87 Est @ 13.98% 52.33
2027 149.76 Est @ 11.87% 51.19
2028 165.33 Est @ 10.4% 49.42
2029 180.82 Est @ 9.37% 47.26
Present value of next 10 years cash flows R$422.00
BOVESPA:PNVL3 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= R$180.82 × (1 + 6.96%) ÷ (14.36% – 6.96%)
R$2,613.55
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= R$2,613.55 ÷ (1 + 14.36%)10
R$683.11
BOVESPA:PNVL3 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= R$422.00 + R$683.11
R$1,105.11
Equity Value per Share
(BRL)
= Total value / Shares Outstanding
= R$1,105.11 / 135.48
R$8.16
BOVESPA:PNVL3 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BOVESPA:PNVL3 represents 1.28393x of BOVESPA:PNVL4
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.28393x
Value per Share
(Listing Adjusted, BRL)
= Value per Share (BRL) x Listing Adjustment Factor
= R$ 8.16 x 1.28393
R$10.47
Value per share (BRL) From above. R$10.47
Current discount Discount to share price of R$25.55
= -1 x (R$25.55 - R$10.47) / R$10.47
-144%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Dimed Distribuidora de Medicamentos is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Dimed Distribuidora de Medicamentos's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Dimed Distribuidora de Medicamentos's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BOVESPA:PNVL3 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in BRL R$0.59
BOVESPA:PNVL4 Share Price ** BOVESPA (2020-04-08) in BRL R$19.9
Brazil Consumer Retailing Industry PE Ratio Median Figure of 5 Publicly-Listed Consumer Retailing Companies 40.83x
Brazil Market PE Ratio Median Figure of 230 Publicly-Listed Companies 11.82x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Dimed Distribuidora de Medicamentos.

BOVESPA:PNVL3 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BOVESPA:PNVL4 Share Price ÷ EPS (both in BRL)

= 19.9 ÷ 0.59

33.83x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dimed Distribuidora de Medicamentos is good value based on earnings compared to the BR Consumer Retailing industry average.
  • Dimed Distribuidora de Medicamentos is overvalued based on earnings compared to the Brazil market.
Price based on expected Growth
Does Dimed Distribuidora de Medicamentos's expected growth come at a high price?
Raw Data
BOVESPA:PNVL3 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 33.83x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
18.1%per year
Brazil Consumer Retailing Industry PEG Ratio Median Figure of 5 Publicly-Listed Consumer Retailing Companies 1.62x
Brazil Market PEG Ratio Median Figure of 117 Publicly-Listed Companies 0.99x

*Line of best fit is calculated by linear regression .

BOVESPA:PNVL3 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 33.83x ÷ 18.1%

1.87x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dimed Distribuidora de Medicamentos is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Dimed Distribuidora de Medicamentos's assets?
Raw Data
BOVESPA:PNVL3 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in BRL R$3.68
BOVESPA:PNVL4 Share Price * BOVESPA (2020-04-08) in BRL R$19.9
Brazil Consumer Retailing Industry PB Ratio Median Figure of 5 Publicly-Listed Consumer Retailing Companies 3.07x
Brazil Market PB Ratio Median Figure of 277 Publicly-Listed Companies 1.16x
BOVESPA:PNVL3 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BOVESPA:PNVL4 Share Price ÷ Book Value per Share (both in BRL)

= 19.9 ÷ 3.68

5.41x

* Primary Listing of Dimed Distribuidora de Medicamentos.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dimed Distribuidora de Medicamentos is overvalued based on assets compared to the BR Consumer Retailing industry average.
X
Value checks
We assess Dimed Distribuidora de Medicamentos's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Consumer Retailing industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Consumer Retailing industry average (and greater than 0)? (1 check)
  5. Dimed Distribuidora de Medicamentos has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

PNVL3 Future Performance

 How is Dimed Distribuidora de Medicamentos expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
18.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Dimed Distribuidora de Medicamentos expected to grow at an attractive rate?
  • Dimed Distribuidora de Medicamentos's earnings growth is expected to exceed the low risk savings rate of 7%.
Growth vs Market Checks
  • Dimed Distribuidora de Medicamentos's earnings growth is expected to exceed the Brazil market average.
  • Dimed Distribuidora de Medicamentos's revenue growth is expected to exceed the Brazil market average.
Annual Growth Rates Comparison
Raw Data
BOVESPA:PNVL3 Future Growth Rates Data Sources
Data Point Source Value (per year)
BOVESPA:PNVL3 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 18.1%
BOVESPA:PNVL3 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 14.4%
Brazil Consumer Retailing Industry Earnings Growth Rate Market Cap Weighted Average 31.3%
Brazil Consumer Retailing Industry Revenue Growth Rate Market Cap Weighted Average 11.1%
Brazil Market Earnings Growth Rate Market Cap Weighted Average 16.8%
Brazil Market Revenue Growth Rate Market Cap Weighted Average 8.6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BOVESPA:PNVL3 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in BRL Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BOVESPA:PNVL3 Future Estimates Data
Date (Data in BRL Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 5,689 1
2023-12-31 4,892 1
2022-12-31 3,944 140 143 3
2021-12-31 3,452 117 105 3
2020-12-31 3,065 48 88 3
2019-12-31
BOVESPA:PNVL3 Past Financials Data
Date (Data in BRL Millions) Revenue Cash Flow Net Income *
2019-09-30 2,638 131 80
2019-06-30 2,562 106 79
2019-03-31 2,500 99 76
2018-12-31 2,432 110 75
2018-09-30 2,359 45 65
2018-06-30 2,317 62 59
2018-03-31 2,282 29 59
2017-12-31 2,258 41 60
2017-09-30 2,238 78 60
2017-06-30 2,191 68 59
2017-03-31 2,146 104 57
2016-12-31 2,129 102 53

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Dimed Distribuidora de Medicamentos's earnings are expected to grow by 18.1% yearly, however this is not considered high growth (20% yearly).
  • Dimed Distribuidora de Medicamentos's revenue is expected to grow by 14.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BOVESPA:PNVL3 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Dimed Distribuidora de Medicamentos Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BOVESPA:PNVL3 Future Estimates Data
Date (Data in BRL Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
BOVESPA:PNVL3 Past Financials Data
Date (Data in BRL Millions) EPS *
2019-09-30 0.59
2019-06-30 0.58
2019-03-31 0.56
2018-12-31 0.55
2018-09-30 0.47
2018-06-30 0.44
2018-03-31 0.43
2017-12-31 0.44
2017-09-30 0.44
2017-06-30 0.43
2017-03-31 0.41
2016-12-31 0.39

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Dimed Distribuidora de Medicamentos is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Dimed Distribuidora de Medicamentos's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Brazil market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Brazil market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Dimed Distribuidora de Medicamentos has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

PNVL3 Past Performance

  How has Dimed Distribuidora de Medicamentos performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Dimed Distribuidora de Medicamentos's growth in the last year to its industry (Consumer Retailing).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Dimed Distribuidora de Medicamentos's year on year earnings growth rate has been positive over the past 5 years.
  • Dimed Distribuidora de Medicamentos's 1-year earnings growth exceeds its 5-year average (23.8% vs 11.8%)
  • Dimed Distribuidora de Medicamentos's earnings growth has exceeded the BR Consumer Retailing industry average in the past year (23.8% vs -39%).
Earnings and Revenue History
Dimed Distribuidora de Medicamentos's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Dimed Distribuidora de Medicamentos Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BOVESPA:PNVL3 Past Revenue, Cash Flow and Net Income Data
Date (Data in BRL Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 2,638.25 79.92 658.08
2019-06-30 2,562.25 78.96 641.87
2019-03-31 2,499.66 75.71 626.16
2018-12-31 2,432.25 74.98 609.17
2018-09-30 2,359.40 64.57 600.68
2018-06-30 2,316.72 59.42 589.35
2018-03-31 2,282.49 58.75 580.03
2017-12-31 2,258.25 59.80 570.99
2017-09-30 2,238.46 59.79 555.54
2017-06-30 2,190.53 58.94 548.12
2017-03-31 2,146.00 56.54 567.95
2016-12-31 2,128.73 53.06 558.39
2016-09-30 2,095.25 52.55 539.32
2016-06-30 2,073.82 49.69 521.98
2016-03-31 2,042.73 49.95 476.11
2015-12-31 1,986.03 45.27 462.11
2015-09-30 1,963.35 43.59 447.47
2015-06-30 1,927.47 42.51 435.92
2015-03-31 1,916.08 47.62 432.20
2014-12-31 1,887.08 49.36 424.44
2014-09-30 1,834.88 49.64 426.98
2014-06-30 1,822.96 57.87 413.53
2014-03-31 1,785.83 54.52 389.90
2013-12-31 1,740.42 56.15 379.46
2013-09-30 1,686.55 53.80 352.05
2013-06-30 1,618.78 48.99 341.62

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Dimed Distribuidora de Medicamentos has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Dimed Distribuidora de Medicamentos used its assets more efficiently than the BR Consumer Retailing industry average last year based on Return on Assets.
  • Dimed Distribuidora de Medicamentos has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Dimed Distribuidora de Medicamentos's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Consumer Retailing industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Dimed Distribuidora de Medicamentos has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

PNVL3 Health

 How is Dimed Distribuidora de Medicamentos's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Dimed Distribuidora de Medicamentos's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Dimed Distribuidora de Medicamentos is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Dimed Distribuidora de Medicamentos's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Dimed Distribuidora de Medicamentos's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 3.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Dimed Distribuidora de Medicamentos Company Filings, last reported 6 months ago.

BOVESPA:PNVL3 Past Debt and Equity Data
Date (Data in BRL Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 498.58 210.77 66.52
2019-06-30 481.82 207.01 56.61
2019-03-31 477.29 136.24 12.23
2018-12-31 463.91 134.10 39.14
2018-09-30 452.75 144.82 10.70
2018-06-30 441.62 142.49 14.78
2018-03-31 437.89 144.66 11.74
2017-12-31 426.75 158.23 58.79
2017-09-30 414.12 93.71 9.78
2017-06-30 406.20 104.08 5.29
2017-03-31 395.40 90.33 17.77
2016-12-31 381.65 87.97 22.34
2016-09-30 372.04 97.52 9.94
2016-06-30 363.74 118.32 31.35
2016-03-31 354.36 110.09 11.75
2015-12-31 344.14 107.88 17.00
2015-09-30 334.99 119.83 12.30
2015-06-30 328.30 126.07 12.49
2015-03-31 316.84 128.90 13.67
2014-12-31 311.30 124.38 24.77
2014-09-30 304.70 109.00 13.70
2014-06-30 299.10 107.33 7.16
2014-03-31 283.94 78.00 12.65
2013-12-31 276.90 62.61 18.89
2013-09-30 269.72 65.98 24.46
2013-06-30 255.81 49.33 8.24
  • Dimed Distribuidora de Medicamentos's level of debt (42.3%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (35.8% vs 42.3% today).
  • Debt is well covered by operating cash flow (61.9%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 5.6x coverage).
X
Financial health checks
We assess Dimed Distribuidora de Medicamentos's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Dimed Distribuidora de Medicamentos has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

PNVL3 Dividends

 What is Dimed Distribuidora de Medicamentos's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.81%
Current annual income from Dimed Distribuidora de Medicamentos dividends.
If you bought R$2,000 of Dimed Distribuidora de Medicamentos shares you are expected to receive R$16 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Dimed Distribuidora de Medicamentos's pays a lower dividend yield than the bottom 25% of dividend payers in Brazil (2.02%).
  • Dimed Distribuidora de Medicamentos's dividend is below the markets top 25% of dividend payers in Brazil (6.38%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BOVESPA:PNVL3 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Brazil Consumer Retailing Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1.3%
Brazil Market Average Dividend Yield Market Cap Weighted Average of 166 Stocks 4.9%
Brazil Minimum Threshold Dividend Yield 10th Percentile 0.9%
Brazil Bottom 25% Dividend Yield 25th Percentile 2%
Brazil Top 25% Dividend Yield 75th Percentile 6.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BOVESPA:PNVL3 Future Dividends Estimate Data
Date (Data in R$) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
BOVESPA:PNVL3 Past Annualized Dividends Data
Date (Data in R$) Dividend per share (annual) Avg. Yield (%)
2019-03-28 0.160 1.240
2018-04-12 0.139 1.753
2017-03-28 0.131 1.327
2016-04-08 0.112 1.631
2015-03-31 0.102 1.994
2014-03-31 0.093 1.736
2013-03-28 0.091 1.479
2012-03-30 0.081 1.740
2011-05-18 0.071 2.447
2011-03-25 0.071 2.544
2010-03-26 0.060 2.908

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dimed Distribuidora de Medicamentos is not paying a notable dividend for Brazil, therefore no need to check if the payments are stable.
  • Dimed Distribuidora de Medicamentos is not paying a notable dividend for Brazil, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Dimed Distribuidora de Medicamentos's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Dimed Distribuidora de Medicamentos's dividends as it is not paying a notable one for Brazil.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Dimed Distribuidora de Medicamentos's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Dimed Distribuidora de Medicamentos afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Dimed Distribuidora de Medicamentos has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

PNVL3 Management

 What is the CEO of Dimed Distribuidora de Medicamentos's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Julio Mottin Neto
CEO Bio

Mr. Julio Ricardo Mottin serves as Chief Executive Officer of Dimed S.A. Distribuidora de Medicamentos and served as its Deputy Chief Executive Officer.

CEO Compensation
  • Insufficient data for Julio to compare compensation growth.
  • Insufficient data for Julio to establish whether their remuneration is reasonable compared to companies of similar size in .
Management Team

Julio Mottin Neto

TITLE
Chief Executive Officer

Roberto Coimbra Santos

TITLE
Chief Administrative Officer

Antônio Carlos Napp

TITLE
Director of Investor Relations

Eduardo Selva

TITLE
Chief Purchasing Officer

João Almeida

TITLE
Chief New Business Officer
Board of Directors

Julio Andrighetto Mottin

TITLE
Chairman of the Board of Directors

Roberto Weber

TITLE
Director

Denis Pizzato

TITLE
Director

Cláudio Ely

TITLE
Director

Pedro de Andrade

TITLE
Director
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (R$) Value (R$)
X
Management checks
We assess Dimed Distribuidora de Medicamentos's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Dimed Distribuidora de Medicamentos has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

PNVL3 News

Simply Wall St News

PNVL3 Company Info

Description

Dimed S.A. Distribuidora de Medicamentos engages in the commercialization of medication, perfumes, personal hygiene and beauty products, cosmetics, and dermocosmetics in Brazil. It operates through Retail, Wholesale, and Corporate segments. The company offers products through distribution centers and stores. It operates 369 stores in Rio Grande do Sul, Santa Catarina, Paraná, and São Paulo in Brazil. The company was formerly known as Panvel S.A. Drogarias e Farmacias and changed its name to Dimed S.A. Distribuidora de Medicamentos in April 2000. Dimed S.A. Distribuidora de Medicamentos was founded in 1920 and is headquartered in Eldorado do Sul, Brazil.

Details
Name: Dimed S.A. Distribuidora de Medicamentos
PNVL3
Exchange: BOVESPA
Founded: 1920
R$3,385,329,816
135,480,390
Website: http://www.dimed.com.br
Address: Dimed S.A. Distribuidora de Medicamentos
Avenida Industrial Belgraff, 865,
Industrial,
Eldorado do Sul,
Rio Grande do Sul, Brazil
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BOVESPA PNVL4 Preferred Shares Bolsa de Valores de Sao Paulo BR BRL 24. Mar 1993
BOVESPA PNVL3 Common Shares Bolsa de Valores de Sao Paulo BR BRL 24. Mar 1993
Number of employees
Current staff
Staff numbers
6,867
Dimed Distribuidora de Medicamentos employees.
Industry
Drug Retail
Consumer Retailing
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 21:31
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/04/08
Last earnings filing: 2019/11/13
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.